Mar 14, 2023 / 02:00PM GMT
Matt Hagood - Oppenheimer & Co. Inc. - Analyst
All right. Good morning, everyone, and welcome to OpCo's 33rd Annual Healthcare Conference. My name is Matt Hagood. I'm on the emerging biotech team here at OpCo. So our next presenting company is Aprea Therapeutics. I'm pleased to be joined by CEO, Oren Gilad. Oren, welcome.
Before we start, I'll just add that if there are any questions from the audience, feel free to type those in the box below your screen. And with that, Oren, the floor is yours.
Oren Gilad - Aprea Therapeutics, Inc. - President & CEO
Thank you, Matt, and thank you for the Oppenheimer team for the invitation to present in the conference. This is our disclosure. Aprea is oncology company focusing on synthetic lethality and the DNA damage response pathway.
We have chosen to target a clinical pathway with multiple targets. So we're looking at the ATR, which our drug is in clinical stage in human, and WEE1, which is in IND-enabling studies. We also have undisclosed programs as well as innovative platform that we're going to
Aprea Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers